Minimally Invasive Surgery in California

Aulea Medical manufactures the Veloxion all-in-one system, a single-use, integrated platform for benign prostatic hyperplasia (BPH) treatment via transurethral resection of the prostate (TURP). The system combines fluid management, video imaging, and radiofrequency energy generation in a single console to streamline urology workflows. Key clinical innovations include automated intravesical pressure monitoring and control, motorized plasma cutting technology, multi-directional resection capability, and immediate tissue evacuation to maintain visualization. The Veloxion is designed to reduce BPH treatment time to approximately 20 minutes compared to standard TURP (60 minutes), enable same-day procedures in ambulatory surgery centers for prostate glands ranging 30–200g, and eliminate infection risk and cross-contamination through single-use endoscopic devices. The system requires minimal setup and teardown, reducing procedure time and cost of ownership. Aulea targets urology departments, ambulatory surgery centers, and specialty urology practices. The company emphasizes safety (pressure management to prevent bladder perforation, sterile single-use design), simplicity (plug-and-play console, automated fluid evacuation), and procedural efficiency. Manufacturing capabilities include single-use device fabrication and integrated RF energy generation systems.

Innova Vascular, Inc. is a medical device company headquartered in Irvine, California, specializing in minimally invasive solutions for treating vascular thromboembolism and peripheral vascular disease. The company develops and commercializes thrombectomy devices targeting acute pulmonary embolism and peripheral arterial occlusions. Core product line: the Laguna Thrombectomy System, which comprises the Laguna Clot Retriever™ System and Malibu Aspiration Catheter™ System. Both devices received FDA 510(k) clearance in June 2023 for use in the peripheral vasculature. Early commercial deployment has been reported at UCLA Medical Center (Los Angeles) and Providence St. Joseph (Orange, California) as of February 2024. The company is actively enrolling clinical sites for the TRUST (Treating Pulmonary Embolism With Laguna Thrombectomy System) study to evaluate the system's safety and efficacy in pulmonary embolism treatment. Founded by Dr. Sanjay Shrivastava, who brings over 20 years of medical device development and commercialization experience from senior roles at Johnson & Johnson, Medtronic, BTG plc, and Covidien/ev3. The leadership team includes board members with expertise in orthopedics, business development, and venture capital, and commercial leadership includes VP of Sales Paul Mullen and Commercial Advisor John Zehren. Regulatory: FDA 510(k) cleared. Founder holds 30+ issued US patents and numerous international patents in medical device design and materials. Markets served: interventional cardiology, peripheral vascular intervention, and acute vascular disease management at teaching hospitals and regional medical centers.

Promaxo is a MedTech company specializing in compact, single-sided portable MRI systems and AI-driven technologies for interventional imaging and image-guided procedures. The company's flagship product is an office-based MRI platform that received FDA clearance in March 2021, enabling real-time MR-guided biopsies and cancer treatment in ambulatory settings without requiring dedicated MRI suites. Promaxo's system is designed for urologists and hospitals targeting prostate cancer diagnosis and treatment, featuring AI-driven tissue characterization with reported 77% cancer detection rates and 33% improvement in detecting clinically significant cancers versus standard of care. The system requires minimal facility upgrades and integrates seamlessly into existing clinical workflows, allowing concurrent clinic operations and interventional procedures. Founded in 2016 and backed by strategic investors including MicroPort and Zepp Health, Promaxo holds over 200 patents and is expanding applications to breast oncology and orthopedics. The company is led by CEO and Chairman Amit Vohra.

Fziomed, Inc. is a global leader in surgical adhesion prevention, founded in 1996 and headquartered in San Luis Obispo, California. The company specializes in developing, manufacturing, and commercializing surgical biomaterials designed to prevent postsurgical adhesions—a common complication following surgical procedures. Fziomed's products utilize proprietary dual-polymer gel technology to create clear, absorbable formulations that provide temporary tissue separation during the healing process, significantly reducing adhesion formation. The company's flagship product, Oxiplex® gel, received FDA De Novo classification and marketing authorization in July 2025 for reducing postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. Fziomed's adhesion barrier products are marketed in over 70 countries and have been utilized in nearly 1 million procedures worldwide since 2002. The product portfolio addresses multiple surgical disciplines including spine surgery, tendon and peripheral nerve procedures, intrauterine surgery, and abdominal/pelvic procedures. With approximately 59 employees, Fziomed maintains full control over both manufacturing and commercialization of its innovative surgical solutions.

STARmed America, Inc. is the U.S. subsidiary of South Korean medical device manufacturer STARmed Co., Ltd., established in October 2023. Based in Los Angeles, the company specializes in FDA-cleared radiofrequency ablation (RFA) systems and electrodes for minimally invasive treatment of soft tissue conditions. STARmed offers four RFA generator systems and over ten types of electrodes, including the pioneering thyroid-dedicated RF electrode first developed in 2004. Products are designed for percutaneous and endoluminal ablation applications across thyroid, liver, kidney, lung, bone, biliary, pancreatic, and uterine fibroid conditions. The company currently supports over 120 medical facilities across 36 U.S. states and has trained more than 300 physicians. STARmed provides comprehensive program support including hands-on training, clinical case assistance, reimbursement guidance, and marketing support, with 96% physician satisfaction rates.

Spinal Elements is a Carlsbad-based medical device company founded in 2004 that develops innovative, proprietary spine surgery technologies for minimally invasive procedures. The company specializes in advanced interbody solutions, metal-free fixation devices, and biologics for TLIF (transforaminal lumbar interbody fusion), ALIF (anterior lumbar interbody fusion), and posterior fixation applications. Their product portfolio includes the Ventana interbody system (available in lumbar and cervical configurations with 3D-printed options), the Luna TLIF portfolio, the Karma metal-free fixation system, the Sapphire X cervical plate system, and comprehensive core and biologics solutions. Spinal Elements operates as a market leader in commercializing spine surgery solutions through proprietary technologies, strategic distributor relationships, and surgeon partnerships. The company manufactures devices for hospital and ambulatory surgery center environments. Multiple products have received FDA 510(k) clearance, including recent clearances for the Ventana ALIF System and Sapphire X expansions. Spinal Elements has achieved notable contracts including a Vizient Innovative Technology Contract for the Karma Fixation System, demonstrating acceptance within major healthcare provider networks. The company maintains a surgeon-centric approach, collaborating with clinical experts to develop patient-first procedural solutions addressing the fastest-growing segments of the spine surgery market.

Altaviz, LLC is a medical device innovation and design firm specializing in advanced drug delivery systems and ophthalmic solutions. Founded in 2012 and based in Irvine, California, the company develops proprietary platform technologies for the medical device, pharmaceutical, and biotechnology sectors. Altaviz offers modular framework solutions including autoinjectors, fluid injectors, gas injectors, and implant delivery systems—all designed for rapid customization to address specific client engineering challenges. The company provides comprehensive services spanning concept development, product engineering, technology transfer, and post-market support. A key innovation focus is medical-grade compressed gas technology for precision drug delivery and therapy applications. Altaviz serves startups through established firms, combining scalable manufacturing expertise with high-performance design to enhance patient safety and clinical outcomes.

Claria Medical develops the Claria System, an intelligent surgical platform designed for safe, minimally-invasive hysterectomy and related gynecological procedures. The system enables extraction of enlarged uteri using a vaginal approach without mini-laparotomy, addressing key clinical challenges in current hysterectomy techniques: container breach risks (potential for hidden cancer spread or bowel injury), significant abdominal scarring, and variable procedure times. The Claria System features redundant safety mechanisms for breach-resistant tissue containment, integrated lighting and blade technology within a large-bore handpiece for rapid extraction of large tissue volumes, and simplified handling to reduce procedural variability. The company has received prestigious National Science Foundation (NSF) and National Institute of Health (NIH) grants for product development. The platform is supported by published clinical evidence, including case reports from international surgical centers (Sydney Women's Endosurgery Centre, Hospital Angeles Morelia), a 30-surgeon usability study, and microbiological studies validating container integrity. Claria Medical targets gynecological surgeons, minimally-invasive surgery specialists, and hospital surgical departments seeking to improve hysterectomy outcomes, reduce patient recovery time, and minimize complications associated with tissue extraction and specimen containment.

Caldera Medical is a U.S.-based medical device manufacturer headquartered in Westlake Village, California, specializing in minimally invasive surgical solutions for women's pelvic health. Founded in 2002, the company develops and markets innovative products for stress urinary incontinence (SUI), pelvic organ prolapse (POP), and hysteroscopic tissue removal. The company's product portfolio includes the Desara® Family for SUI treatment, the Vertessa® Family for POP repair, the Benesta Family for hysteroscopic procedures, and the Luminelle system launched in 2024 for advanced gynecological applications. Recognized as the fastest-growing women's health company for three consecutive years, Caldera Medical emphasizes surgeon collaboration, physician training, and clinical support. The company is committed to improving patient outcomes through durable, effective minimally invasive treatments while supporting a global humanitarian program aimed at reaching one million women with pelvic health education and treatment by 2027.

Renata Medical is a MedTech startup headquartered in Newport Beach, California, specializing in minimally invasive medical devices for pediatric cardiology. Founded in 2019, the company develops innovative solutions to address unmet clinical needs in congenital heart disease and pediatric vascular stenosis. The flagship product, Minima Growth Stent System, is the first and only FDA-approved stent designed specifically for infants weighing over 1.5 kg. This breakthrough device features a gradual re-expansion mechanism that accommodates a child's growth from infancy through adulthood, eliminating the need for multiple interventional procedures. Minima represents a transcatheter alternative to traditional open-heart surgery, reducing operative burden while improving long-term outcomes in the neonatal and pediatric population. Renata Medical's leadership comprises experienced professionals with deep expertise in transcatheter devices and pediatric cardiology, ensuring clinically relevant product development and market deployment strategies.

Levita Magnetics International Corp. is a medical device company specializing in magnetic surgical technology for minimally invasive procedures. The company's flagship product, MARS™ (Magnetic Autonomously Retractable System), is a first-of-its-kind robotic surgical platform that leverages magnetic technology to enhance precision and accessibility in surgical care. MARS has received FDA clearance and represents a novel approach to minimally invasive surgery by harnessing magnetic and robotic mechanisms. The platform has been deployed in commercial surgical cases and recent applications include AI-guided autonomous surgical camera systems that enhance procedural precision and efficiency. Levita Magnetics markets its technology to hospitals and surgical centers seeking to expand minimally invasive surgical capabilities and improve patient outcomes through advanced magnetic surgery techniques. The company emphasizes patient accessibility and the reduction of surgical invasiveness as core mission drivers.

SPIWay, LLC is a medical device company specializing in access technologies and surgical visualization systems for minimally invasive neurosurgery. The company develops the SPIWAY EAG (Endonasal Assisted Glioma) Platform, a technology designed to improve surgical visualization during endoscopic endonasal approaches (EEA) for neurosurgical procedures. The platform integrates advanced visualization capabilities to support surgeons performing minimally invasive intracranial interventions. SPIWay markets the EAG Platform to neurosurgery departments and specialized surgical centers. The company provides clinical evidence and training resources to support adoption and proper utilization of their technology. While specific regulatory certifications are not mentioned in the available website content, the company operates as a medical device manufacturer serving the neurosurgical market.

ATEC Spine (Alphatec Holdings, Inc.) is a spinal surgery device manufacturer specializing in innovative interbody fusion systems and surgical technologies. The company develops porous titanium interbody spacers, including the IdentiTi II LIF platform, designed for anterior and posterior spinal fusion procedures. ATEC's product portfolio encompasses procedural technologies across multiple spine surgery approaches: anterior cervical discectomy and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), posterior cervical fusion (PCF), lateral transpsoas (LTP), prone transpsoas (PTP), posterior lumbar interbody fusion (PLIF), posterior fixation, and corpectomy. The company positions itself as a revolutionizer of spine surgery approaches with intentional, integrated, and individualized design principles. ATEC Spine serves spine surgeons and hospitals performing complex spinal procedures, competing in the orthopedic implant and minimally invasive spine surgery segment. The company reported full-year 2025 total revenue of $764 million with 25% growth, demonstrating significant market presence. ATEC maintains an active presence at major spine surgery societies and regional symposia, engaging surgeons on procedural innovation and clinical outcomes. The company emphasizes surgeon-driven education, data-informed decision-making, and procedural discipline in spinal fusion techniques.

HK Surgical is a leader in the development, distribution, and marketing of liposuction and fat harvesting/grafting surgical supplies, founded in 1998 by Dr. Jeffrey Klein. The company specializes in equipment and supplies for tumescent local anesthesia procedures, including the proprietary Klein Infiltration Pump (available in multiple models: KIP-II+, KTDD). HK Surgical offers a comprehensive product portfolio encompassing infiltration and aspiration pumps, surgical cannulas (reusable and single-use), fat collection and transfer systems, infiltration tubing sets, positioning pillows, super-absorbent surgical pads, OR table sheets, compression garments, and catheter sets. The company serves plastic surgeons, physicians, nurses, and patients, emphasizing superior quality, reliability, and value. Products are FDA-approved and designed for liposuction, body contouring, varicose vein ablation, and facial procedures. HK Surgical provides same-day shipping on orders placed by 1 PM PST and offers live customer support.